Abstract. During random screening for chondrogenic differentiation inducers, we found that Compound-1, 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1 H -pyrazol-3-yl]benzene-1,3-diol, initiated chondrogenic differentiation of the chondroprogenitor cell line ATDC5. Compound-1 initiated chondrogenic differentiation of the mesenchymal stem cell line C3H10T1/2 in regions where cell aggregates formed and simultaneously inhibited adipogenic differentiation. In C3H10T1/2 cells, Compound-1 increased the expression of Sry-related high-mobility-group box transcription factors L-SOX5, SOX6, and SOX9 (SOX trio) more strongly than bone morphogenic protein (BMP)-2. cAMP-dependent protein kinase (PKA) inhibitors suppressed Compound-1-dependent L-SOX5 and SOX6 up-regulation. PKA inhibitors also suppressed the up-regulation of aggrecan mRNA induced by Compound-1, indicating that increases in L-SOX5 and SOX6 mRNA, in which the PKA pathway participates, are involved in the mechanisms behind the action of Compound-1. On the other hand, the SOX6 and aggrecan gene expression, which were up-regulated by BMP-2, were not affected by the PKA inhibitor. Compound-1 induced chondrogenic differentiation of bone marrow stromal cells and recovered cartilage matrix production by primary chondrocytes, which had been decreased by interleukin-1 β . These results show the potential of Compound-1 to be a new cartilage repair agent for inducing chondrogenic differentiation via SOX trio up-regulation.
Introduction
Self-regeneration of cartilage damaged by injury or osteoarthritis cannot be fully expected because of its poor intrinsic healing capacity (1) . One reason for this is that the limited number of chondrocytes in wounded regions is not sufficient to produce enough cartilage matrices for repair (2) .
Promotion of chondrogenic differentiation is one way of increasing the number of chondrocytes (3) . Chondrocytes are derived from mesenchymal stem cells present in bone marrow stromal cells, which are common progenitor cells of osteoblasts, myoblasts, and adipocytes (4) . These mesenchymal stem cells commit to becoming chondroprogenitors, form aggregates, and then differentiate into chondrocytes (5) .
Various cell lines are used to research chondrogenic differentiation according to their differentiation stage and pattern. Among the cell lines, murine embryonal carcinoma-derived ATDC5 is one of the most useful chondroprogenitor-like cell lines as it faithfully reproduces the chondrogenic differentiation steps (6) . ATDC5 cells treated with insulin continue growth in the postconfluent phase and form cartilaginous nodules that differentiate into mature chondrocytes characterized by the expression of marker genes such as type II collagen (Col2a1) and aggrecan (Agc1). Another cell line, C3H10T1/2, is a mesenchymal stem cell line derived from mouse embryos (7) . Due to their multipotent capacity to differentiate into various cell types including chondrocytes, adipocytes, osteoblasts, and myoblasts, C3H10T1/2 cells are frequently used for research into chondrogenic differentiation including commitment.
The Sry-related high-mobility-group box transcription factors L-SOX5, SOX6, and SOX9 (SOX trio) are master genes for chondrogenic differentiation (8, 9) . SOX9 is expressed in all chondroprogenitors and chondrocytes except hypertrophic chondrocytes. SOX9 participates in both cell aggregation and chondrogenic differentiation. L-SOX5 and SOX6 are expressed from prechondrocytes under the control of SOX9 and enhance chondrogenic specific gene transcription cooperatively with SOX9. Bone morphogenic proteins (BMP), which were originally identified by their ability to induce de novo ectopic bone formation, are involved in two steps of chondrogenic differentiation, the aggregation of mesenchymal stem cells and the maturation of chondrocytes (10) . BMP-2 is reported to up-regulate SOX9 and SOX6 expression as a means of inducing chondrogenic differentiation (11, 12) .
Previously, some low molecular weight compounds were reported to promote chondrogenic differentiation (13 -15) . Among these compounds, tacrolimus (FK506) showed activities to induce chondrogenic differentiation of ATDC5 cells in the absence of insulin, indicating its initiation activity of chondrogenic differentiation (15) . The mechanisms of FK506 to induce chondrogenic differentiation are not well elucidated. However, FK506 initiated chondrogenic differentiation through a mechanism independent of SOX trio up-regulation or activation in the cells (15) . From random screening, we discovered Compound-1, 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1 H -pyrazol-3-yl]benzene-1,3-diol, as a new chondrogenic differentiation initiator. Investigation of its mechanism revealed that Compound-1 induced chondrogenic differentiation via SOX trio up-regulation.
Materials and Methods

Materials
Compound-1 (Fig. 1A ) was synthesized by Takeda Pharmaceutical Company. Recombinant human Interleukin (IL)-1 β , L -ascorbic acid, L -ascorbic acid phosphate magnesium salt, β -glycerophosphate, dexamethasone, and citrate were purchased from Wako Pure Chemical Industries (Osaka). H-89, D-MEM/F-12 medium, α -minimum essential ( α -MEM) medium, CMRL-1066 medium, pyruvate, and bovine insulin were bought from Invitrogen (Walkersville, MD, USA). Fetal bovine serum (FBS), Rp-isomer of adenosine 3′,5′monophosphorothio-ate (Rp-cAMP), and recombinant human BMP-2, were purchased from BioWhittaker (Walkersville, MD, USA), Biolog Life Science Institute (La Jolla, CA, USA), and R&D Systems (Minneapolis, NI, USA), respectively. 
Control
Compound-1 Insulin
Cell culture ATDC5 cells (Riken Cell Bank, Ibaraki) were maintained and subcultured as previously described (6) . For random screening, we seeded 1.6 × 10 4 cells/well in 200 µ l D-MEM/F-12 medium containing 5% FBS and 1 ng/ ml basic fibroblast growth factor (PeproTech, London, UK) in a 96-well suspension culture U-bottomed plate (Sumitomo Bakelite, Tokyo). For measurement of the amount of proteoglycan accumulation, the cells were seeded in a 35-mm suspension culture dish (Sumitomo Bakelite) at 4 × 10 4 cells/ml cell density in 3 ml D-MEM/F-12 medium containing 5% FBS. The medium was changed every 3 days. C3H10T1/2 cells (Riken Cell Bank) were maintained and subcultured in D-MEM/F-12 medium containing 10% FBS. For differentiation analyses, the cells were plated in a 24 multi-well plate in CMRL-1066 medium containing 15% FBS, 2 mM L -Glutamine, 50 µ g/ml pyruvate, 50 µ g/ml citrate, and 50 µ g/ml L -ascorbic acid phosphate magnesium salt. The plating density was 2 × 10 5 cells/well in 1 ml medium. The medium was changed every 3 days. Rat bone marrow stromal cells were obtained from the femoral bone marrow of 7-week-old male Sprague-Dawley rats (Japan Charles River, Tokyo) (16) . The cells were cultured in a 100-mm tissue culture dish with pre-culture medium (D-MEM/F-12 + 10% FBS). Nonadherent blood cells were removed during the medium changes performed every other day. After 7 days culturing, the confluent cells were subcultured in a 6-well multi dish ( α -MEM medium + 15% FBS, 2 mM glutamine, 50 µ g/ml of ascorbic acid, 10 mM β -glycerophosphate, and 0.1 µ M dexamethasone) at a cell density of 4 × 10 4 cells/well. Rabbit growth-plate chondrocytes were isolated from the rib cartilages of 3-to 4-week-old male Japan white rabbits (Japan Charles River) as described previously (17, 18) . The cells were plated on a 96-well Matrigel plate (BD Biosciences, San Jose, CA, USA) at 1.5 × 10 5 cells/ well in 150 µ l of α -MEM medium + 10% FBS. The next day, 1 ng/ml IL-1 β and Compound-1 were added to the media. After 4 days culture, 8 M guanidine-HCl / 0.1 M Tris-HCl buffer was directly add to wells to lyse all the synthesized proteoglycans.
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA of the cells were isolated with the RNeasy kit (Qiagen, Tokyo). For semi-quantitative RT-PCR analysis, first-strand cDNAs were synthesized with random hexamers using the RNA PCR kit (Takara Bio, Otsu). Gene-specific primers used in this experiment are summarized in 
, and adipsin (Mm00442664_m1) using ABI PRISM 7900HT sequence detection systems (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin expression were examined by TaqMan ® Rodent GAPDH Control Reagents and mouse ACTB endogenous control reagent (Applied Biosystems), respectively.
Measurement of cartilage-specific proteoglycan
The cartilage-specific proteoglycans produced by ATDC5 cells and rabbit primary chondrocytes were measured by color reaction with dimethylmethylene blue as previously described (19) . Another method was used for measurement of proteoglycan production by C3H10T1/2 cells and rat bone marrow stromal cells (16) . The cells fixed with methanol (2 min, −20°C) were stained overnight at room temperature with 0.3% Alcian Blue (Alcian Blue 8 GX; Sigma, St. Louis, MO, USA) in 0.1 N HCl. On the day after taking the pictures, the cellassociated dye was extracted with 6 M guanidine-HCl to measure absorption at 630 nm.
Statistical analyses
Statistical analysis was performed with statistical analysis software (SAS pre-clinical package, version 5.0; SAS Institute, Inc., Cary, NC, USA). Values are expressed as the mean ± S.D. and were statistically analyzed using the unpaired Student's t -test or parametric Williams' test. 
Results
Effect of Compound-1 on chondrogenic differentiation of ATDC5 cells
The ATDC5 cells required a long culture period and frequent medium changes for differentiation (6) , which interfered with the use of the cells in random compound screening. To construct an evaluation system adaptable to compound screening, we tried performing an ATDC5 cell suspension culture. Under the conditions, we observed that ATDC5 cells formed enlarged cell aggregates (Fig. 1B) and increased Agc1 and Col2a1 mRNA in the presence of insulin by day 6, indicating their chondrogenic differentiation (Fig. 1C) . We did not observe these chondrogenic marker expression changes for 6 days in the absence of insulin (Fig. 1C) ; therefore, we performed random screening for compounds capable of initiating chondrogenic differentiation using ATDC5 cells in suspension without insulin stimulation using increases in the expression of these genes as differentiation markers at day 6. We found that Compound-1 increased Agc1 and Col2a1 mRNA expression (Fig. 1C) . The up-regulation of Agc1 mRNA was observed significantly at 1 and 10 µ M on day 3 and at 0.1 -10 µ M on day 6. Significant upregulation of Col2a1 mRNA was observed at 1 and 10 µ M on days 3 and 6. We observed higher induction on day 6 than on day 3 for both genes. We examined the effect of Compound-1 on proteoglycan accumulation in ATDC5 cells (Fig. 1D) . After culturing the cells for 15 days, 10 µ M Compound-1, which induced a significant increase in Agc1 and Col2a1 mRNA expression as shown in Fig.  1C , significantly increased proteoglycan accumulation; and 0.1 µ M Compound-1, which slightly increased Agc1 and Col2a1 mRNA expression, also increased proteoglycan accumulation but not significantly (Fig. 1D) . The cell aggregates enlarged with Compound-1 stimulation (Fig.  1B) . These results indicate that Compound-1 initiated and induced chondrogenic differentiation of ATDC5 cells accompanied by aggregate formation.
Effect of Compound-1 on chondrogenic differentiation of C3H10T1/2 cells
We examined the effects of Compound-1 on chondrogenic differentiation including the commitment step using C3H10T1/2 cells. Compound-1 concentrationdependently increased Agc1 mRNA on days 3 and 6 in C3H10T1/2 cells ( Fig. 2A) . The increases were significant at 1 and 10 µ M on both days. Compound-1 did not change Col2a1 mRNA expression by day 3 but had increased it concentration-dependently by day 6 (Fig. 2A) . The increase seen on day 6 was significant at 1 and 10 µ M. Proteoglycans accumulated in the areas where cell aggregations had formed in the Compound-1-treated cells (Fig. 2B) . We did not observe cell aggregation or proteoglycan accumulation in the Compound-1-untreated cells. The increase of proteoglycans in the Compound-1-treated cells was concentration-dependent ( previously reported to induce chondrogenic differentiation of C3H10T1/2 cells (12), increased proteoglycan accumulation (Fig. 2C) . The amount of proteoglycans in the 10 µ M Compound-1-treated cells was similar to that in the 10 ng/ml BMP-2-treated cells. BMP-2 also increased the levels of Agc1 and Col2a1 mRNA by days 3 and 6 ( Fig. 2A) . Comparing the effect of 10 µ M Compound-1 to 10 ng/ml BMP-2 on the expression of the genes, Compound-1 and BMP-2 up-regulated Col2a1 expression at a similar level, whereas, Compound-1 upregulated Agc1 mRNA more effectively than BMP-2 at day 6 ( Fig. 2A) . (Fig. 3) . These results indicate that Compound-1 initiated and induced chondrogenic differentiation of C3H10T1/2 cells via cell aggregation steps.
Effect of Compound-1 on the adipogenic differentiation of C3H10T1/2 cells
C3H10T1/2 cells have the potential to differentiate into adipocytes. Under the conditions used to investigate the effects of Compound-1, we observed increases in the expression of the adipocyte marker genes. LPL and adipsin increased from day 3 to day 6 (LPL: 925%, adipsin: 9610%), indicating their spontaneous adipogenic differentiation. Compound-1 suppressed LPL and adipsin mRNA expression significantly at day 6 (Fig. 4) . This result suggests that Compound-1 suppressed adipogenic differentiation instead of initiating chondrogenic differentiation.
Induction of SOX trio expression by Compound-1 involving cAMP-dependent protein kinase (PKA) pathway
SOX trio are important transcriptional factors that control chondrogenic differentiation. To explore the mechanism of Compound-1, we examined SOX trio expression in C3H10T1/2 cells. Compound-1 (10 µ M) significantly up-regulated the L-SOX5, SOX6, and SOX9 mRNA expressions of the cells after 2 days culture (Fig. 5) . For further elucidation of the mechanism, we searched for a signaling pathway that affected SOX trio expression. We found that H-89, a strong PKA inhibitor, partially suppressed the up-regulation of L-SOX5 and SOX6 expression induced by Compound-1, whereas, it did not affect the basal expression levels of these genes (Fig. 5) . H-89 also suppressed the up-regulation of Agc1 expression induced by Compound-1 (Fig. 5) . However, H-89 suppressed basal Agc1 mRNA expression as well; therefore, the role of PKA in Compound-1-dependent Agc1 mRNA up-regulation was unclear. To clarify the involvement of the PKA pathway in Compound-1-induced chondrogenic differentiation, we examined the effect of Rp-cAMP, a PKA-specific inhibitor, on SOX trio and Agc1 expressions. Rp-cAMP at 500 µ M significantly suppressed L-SOX5, SOX6, and Agc1 expressions in the presence of Compound-1, but did not affect their basal expression levels (Fig. 5) . Neither basal nor Compound-1-induced SOX9 expression was affected by H-89 or Rp-cAMP (Fig. 5) . These results suggest that Compound-1 induced chondrogenic differentiation at least partially via L-SOX5 and/or SOX6 up-regulation, 
Induction of SOX trio expression by BMP-2
BMP-2 is reported to induce chondrogenic differentiation of C3H10T1/2 cells via SOX6 induction. To compare the mechanism of Compound-1 to that of BMP-2, we examined SOX trio expression and the effect of Rp-cAMP in BMP-2-treated C3H10T1/2 cells. In these cells, Agc1 expression showed concentration-dependent increases in the range from 10 to 250 ng/ml of BMP-2 (Fig. 6A) . We also observed significant increases of SOX6 and SOX9 mRNA expression by BMP-2 treatment; however, they peaked at 50 ng/ml (Fig. 6A ) and the induction levels were lower than those of the 10 µ M Compound-1-treated cells. L-SOX5 mRNA did not increase after BMP-2 treatment. Rp-cAMP at 500 µ M did not affect BMP-2-dependent SOX6 or Agc1 up-regulation (Fig.  6B) . These results suggest that Compound-1 increased SOX trio expression more strongly than BMP-2.
Effect of Compound-1 on BMP expression of C3H10T1/2 cells
To elucidate the participation of BMP mRNA induction in Compound-1 ability, we examined BMP-2, -4, and -7 mRNA expressions of C3H10T1/2 cells by quantitative RT-PCR. We detected these gene expressions in the cells cultured for 2 days neither in the absence nor in the presence of 10 µ M Compound-1 (data not shown). These results suggest that Compound-1 did not induce chondrogenic differentiation of C3H10T1/2 cells via BMP-2, -4, and -7 mRNA up-regulation.
Effect of Compound-1 on rat bone marrow stromal cells
In vivo, chondrocytes differentiate from progenitor cells present in bone marrow stromal cells. We evaluated the potential of Compound-1 to stimulate chondrogenic differentiation of rat bone marrow stromal cells. As shown in Fig. 7A , a concentration-dependent increase in proteoglycan accumulation was observed in Compound-1-treated rat bone marrow stromal cells. Agc1 and Col2a1 mRNA expressions were up-regulated in the presence of 10 µ M Compound-1 (Fig. 7B) . These results indicate that Compound-1 induces chondrogenic differentiation of rat bone marrow stromal cells.
Effects of Compound-1 on dedifferentiated chondrocytes
We examined the effect of Compound-1 on proteoglycan production from primary chondrocytes. Compound-1 at 10 µ M significantly increased proteoglycan production at 1.3-fold (Fig. 8) . In osteoarthritis cartilage, IL-1 is reported to be an important factor that decreases cartilage matrix production by stimulating the dedifferentiation of chondrocytes (20) . To investigate the effect of Compound-1 on proteoglycan production from chondrocytes under the osteoarthritis condition, we also examined the effect of Compound-1 on rabbit primary chondrocytes stimulated with IL-1 β . IL-1 β at 10 ng/ml decreased proteoglycan production from rabbit chondrocytes (Fig. 8) . Compound-1 at 10 µ M significantly increased proteoglycan production at 3.5-fold in the presence of IL-1 β (Fig. 8) . These results indicate that Compound-1 increased proteoglycan production from primary chondrocytes in the absence or presence of IL-1 β .
Discussion
In this report, we described the potential of Compound-1 as a new cartilage repairing agent that enhances cartilage matrix production by stimulating chondrogenic differentiation. This potential is supported by three findings: 1) Compound-1 initiated chondrogenic differentiation of progenitor cells including the commitment step in a similar manner to in vivo chondrogenic differentiation accompanied by aggregation steps, 2) Compound-1 induced chondrogenic differentiation of bone marrow stromal cells containing chondroprogenitors, and 3) Compound-1 recovered cartilage matrix production from primary cells dedifferentiated by IL-1 β . We also described the mechanism of the induction of chondrogenic differentiation by Compound-1. Compound-1 increased SOX trio expression, which are master genes for chondrogenic differentiation in C3H10T1/2 cells. Compound-1 up-regulated L-SOX5 and SOX6 mRNA through a different mechanism from BMP-2, which was reported to control chondrogenic differentiation by SOX6 expression.
We used the suspension culture of ATDC5 cells to evaluate the effect of the test compounds on chondrogenic differentiation. ATDC5 cells cultured without insulin stop growing and do not differentiate into chondrocytes in the culture condition. The cells formed enlarged aggregates and increased chondrocyte marker genes in the presence of insulin at day 6. These results indicate that the ATDC5 cells cultured in suspension formed cell aggregates that differentiated into chondrocytes upon insulin stimulation in a similar manner to the adherent cultured ATDC5 cells previously described (6) . Compound-1 induced aggregate enlargement and chondrogenic marker gene expression of ATDC5 cells followed by the production of a proteoglycan matrix in the absence of insulin. These results suggest that Compound-1 initiates the chondrogenic differentiation of ATDC5 cells accompanied by cell aggregation. To confirm the initiation activity of Compound-1, we investigated its effects on a mesenchymal stem cell line, C3H10T1/2. Compound-1 initiated chondrogenic differentiation of the cells in the regions where cell aggregation occurred. This result suggested that Compound-1 initiated the chondrogenic differentiation of the cells followed by cell aggregation. The differentiation-inducing We evaluated the effect of Compound-1 on the primary cells. Chondrocytes are differentiated from progenitor cells present in the bone marrow stroma in vivo. Compound-1 induced chondrogenic differentiation of rat bone marrow stromal cells, suggesting its potency for inducing chondrogenic differentiation in in vivo progenitors. Compound-1 recovered proteoglycan production from rabbit primary chondrocytes dedifferentiated by IL-1 β , which was previously reported to be active in osteoarthritis patient joints and to reduce cartilage matrix production by inducing the dedifferentiation of chondrocytes (20, 21) . This result suggests that Compound-1 is able to restore cartilage matrix production from chondrocytes in osteoarthritis patient joints, possibly by inducing redifferentiation of the cells.
We discovered that Compound-1 increased SOX trio mRNA expression in C3H10T1/2 cells. The SOX trio are transcriptional factors controlling chondrogenic differentiation; therefore, the up-regulation of this SOX trio might be one of the mechanisms by which Compound-1 initiates chondrogenic differentiation. In particular, SOX9 is reported to participate in cell aggregation and chondrogenic differentiation (8), L-SOX5 and SOX6 expression (9) , and chondrocyte-specific gene expression in dedifferentiated chondrocytes (22) ; therefore, all of the phenomena that we observed in the Compound-1-treated cells can be accounted for by SOX9 up-regulation.
During further elucidation of the mechanism, we found that the PKA inhibitors H-89 and Rp-cAMP suppressed the L-SOX5 and SOX6 mRNA up-regulation induced by Compound-1, but did not affect L-SOX5 or SOX6 basal expression. These results indicate the participation of the PKA pathway in the up-regulation of L-SOX5 and SOX6 by Compound-1. At the same time, we observed that both inhibitors suppressed the Agc1 expression stimulated by Compound-1. Taken together, these results indicate that Compound-1 induces Agc1 expression by up-regulating L-SOX5 and SOX6 mRNA. Rp-cAMP did not affect the Agc1 basal expression level, but H-89 decreased its expression. H-89 is reported to inhibit kinases other than PKA (23) . H-89 target kinase(s) might participate in basal Agc1 expression. The mechanisms by which PKA is involved in Compound-1-induced L-SOX5 and SOX6 expressions are still unclear. PKA inhibitors did not affect SOX9 expression; therefore, the direct activation of the PKA pathway might not to be a mechanism behind the action of Compound-1. L-SOX5 and SOX6 mRNA expressions are reported to be induced by SOX9 activity, and PKA is reported to increase SOX9 activity via direct phosphorylation of the SOX9 protein (8) . Compound-1 might increase the level of phospho-SOX9 protein via SOX9 mRNA up-regulation, which leads to L-SOX5 and SOX6 mRNA expressions.
BMP-2 was previously reported to induce chondrogenic differentiation of C3H10T1/2 cells by increasing SOX6 expression (12) . To compare the mechanism of Compound-1 to that of BMP-2, we examined SOX trio expression in BMP-2-treated C3H10T1/2 cells. We observed SOX6 and SOX9 up-regulations after BMP-2 treatment as previously reported (11, 12) . However, the expression levels of those genes induced by BMP-2 were lower than those induced by Compound-1, and we did not observe significant up-regulation in L-SOX5 expression by BMP-2, indicating that the ability of Compound-1 to induce SOX trio expression is stronger than that of BMP-2. The up-regulations of SOX6 and Agc1 expression induced by BMP-2 were not suppressed by 500 µ M Rp-cAMP, which was sufficient to repress the genes up-regulated by Compound-1, suggesting that the PKA pathway, which participates in Compound-1-induced chondrogenic differentiation, is not involved in BMP-2-induced chondrogenic differentiation. Our observations that 10 ng/ml BMP-2 produced a similar level of chondrogenic differentiation to 10 µ M Compound-1, but was less active towards Agc1 gene expression, support the existence of different mechanisms for Compound-1 and BMP-2. The lack of L-SOX5 induction in BMP-2-treated cells indicates that the activities of Compound-1 are not mediated by endogenous BMP-2 induction or activation. Compound-1 did not induce BMP-2, -4, and -7 mRNA expressions, suggesting these gene up-regulations did not participate in the Compound-1-induced chondrogenic differentiation. However, the induction or activation of another BMP might be involved in Compound-1-induced chondrogenic differentiation. An experiment using BMP antagonists would be useful to clarify this.
Recently, FK506 was reported to initiate chondrogenic differentiation (15) . In the report, FK506 initiated chondrogenic differentiation through a mechanism independent of SOX trio up-regulation or activation, differently from Compound-1. Thus, Compound-1 could be used as a cartilage repair agent that acts via a new mechanism for SOX trio up-regulation to induce chondrogenic differentiation.
